WeissLaw LLP Investigates SteadyMed Ltd.

NEW YORK, May 2, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of SteadyMed Ltd. ("STDY" or the "Company") (NASDAQ: STDY) in connection with the proposed acquisition of the Company by United Therapeutics Corporation.  Under the terms of the acquisition agreement STDY shareholders will receive $4.46 per share, and an additional $2.63 per share upon the achievement of a milestone related to the commercialization of STDY's Trevyent for each share they own. 

WeissLaw is investigating whether STDY's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at least one analyst set a target price of $15.00 per share. 

Given these facts, WeissLaw is investigating whether STDY's Board acted in the best interests of STDY's public shareholders to maximize shareholder value prior to entering into the agreement.  If you own STDY shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at stockinfo@weisslawllp.com. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com or fill out the form on our website, http://www.weisslawllp.com/steadymed-ltd/

View original content:http://www.prnewswire.com/news-releases/weisslaw-llp-investigates-steadymed-ltd-300641611.html

SOURCE WeissLaw LLP